News & Analysis as of

Health law-news General Business

Read need-to-know updates, commentary, and analysis on Health issues written by leading professionals.
Akerman LLP - HR Defense

GLP-1 Medications: What Employers Need to Know About Rising Costs, Coverage Choices, and Managing Legal Risks

GLP-1 medications, originally developed for diabetes and now widely used for weight management, are rapidly becoming a major cost concern for employer health plans. Annual costs per user often exceed $10,000, and demand is...more

Mandelbaum Barrett PC

Elder Law, Probate Litigation and Special Needs Newsletter: January 2026 Issue

Mandelbaum Barrett PC on

When DNA Tests Meet Estate Plans: Surprise Heirs and the Legal Fallout - For many families, at-home DNA testing kits like 23andMe and Ancestry.com have provided fascinating insights into ancestry and genetic health. But...more

Baker Donelson

New Medicare Requirements for Off-Campus Provider-Based Departments: Separate NPIs and Attestations Required by January 1, 2028

Baker Donelson on

Introduction and Summary - As part of the Consolidated Appropriations Act, Congress established new identification and attestation requirements for off-campus outpatient departments of acute care hospitals. Although Medicare...more

Arnall Golden Gregory LLP

2026 Healthcare M&A: What’s Changed, What’s Working, And Where Deals Are Moving

Key Takeaways - Healthcare M&A activity is rebounding in 2026, but with higher execution standards. Capital is returning to the market, particularly in the middle market, but investors are prioritizing proven operating...more

Oberheiden P.C.

Reporting Medicare Fraud: Program Information and FAQs

Oberheiden P.C. on

Healthcare workers, billing specialists, and medical professionals frequently encounter fraudulent practices that drain billions of dollars from Medicare programs annually. Yet many individuals who witness these schemes...more

Holland & Knight LLP

Holland & Knight Health Dose: February 10, 2026

Holland & Knight LLP on

U.S. Congress will largely return to normal operations this week, following passage of an appropriations package on February 3, 2026, that will fund the vast majority of federal agency operations through the end of 2026. ...more

McDermott Will & Schulte

JPM briefing: Life sciences investors cautiously optimistic for 2026 and beyond

The life sciences investment climate is looking up, as industry adapts to challenging supply-side forces and AI makes inroads in healthcare....more

Kelley Drye & Warren LLP

Ultra-Processed Foods and Consumer Protection: What We Learned from … West Virginia

Our most recent installment of Kelley Drye’s State Attorney General Webinar Series featured a conversation with representatives of the West Virginia Attorney General’s Office, including Chief Deputy Jace Goins, Consumer...more

Brooks Pierce

Brooks Pierce Capital Dispatch: Things to Watch in Raleigh This Year

Brooks Pierce on

North Carolina state government leaders this year are likely to consider important issues including a state budget bill, funding for education and health care (including Medicaid), and various policy issues....more

Hogan Lovells

Life Sciences Law Update Key developments for pharma and medical device companies in EU and Germany, France, UK, Italy and Spain...

Hogan Lovells on

The Q1 and Q3 Life Science and Health Care Law Update covers key trends in the EU only while the other reports (on Q2 and Q4) cover key trends in the EU as well as in the Big Five (France, Germany, Italy, Spain, UK) in life...more

Parker Poe Adams & Bernstein LLP

Clarity for Providers on the February 16 Changes to Notice of Privacy Practices Requirements

Unless your medical practice “creates or maintains” substance use disorder (SUD) records covered by federal law (42 CFR Part 2), you can ignore the barrage of panic-inducing emails you have been receiving informing you that...more

McDermott Will & Schulte

This Week in 340B: January 27 – February 2, 2026

Find the week’s updates on 340B litigation to help you stay in the know on how 340B cases are developing across the country. Each week we comb through the dockets of more than 50 340B cases to provide you with a quick summary...more

Benesch

Dental/DSO Intelligence Monthly Report: February 2026

Benesch on

Across late December 2025 and early January 2026, multiple developments point to a broad tightening of standards and oversight that directly affects DSOs as they scale. At the industry level, the ADA’s decision to launch a...more

TNG Consulting

Intersection of Disability Services and Threat Assessment

TNG Consulting on

Many Title IX coordinators, directors of disability services, and conduct officers serve on Behavioral Intervention Teams (BITs) or Threat Assessment Teams (TATs), and their roles bring valuable perspectives. Sometimes, their...more

McGuireWoods LLP

Understanding Congress’ Latest Extension of Medicare Telehealth Flexibilities

McGuireWoods LLP on

On Feb. 3, 2026, President Donald Trump signed into law the FY 2026 appropriations bill, the Consolidated Appropriations Act of 2026, which extends pandemic-era Medicare telehealth flexibilities through Dec. 31, 2027....more

BakerHostetler

[Podcast] Regulatory Horizons: Cybersecurity and FDA Regulated Companies

BakerHostetler on

Cybersecurity is no longer just an IT or privacy issue. For FDA regulated companies, it’s a patient safety issue, a product quality issue, and increasingly a regulatory enforcement issue. FDA has made it clear that...more

Warner Norcross + Judd

PBM Reform is Here: What CAA 2026 Means for Employer Health Plans

Warner Norcross + Judd on

On Feb. 3, 2026, President Donald Trump signed into law the Consolidated Appropriations Act, 2026 (CAA 2026), a sweeping piece of legislation including provisions that will substantially impact employer-sponsored health...more

Blank Rome LLP

Novo Nordisk Files Patent Infringement Suit Involving Compounded Semaglutide Products

Blank Rome LLP on

Novo Nordisk filed suit in the U.S. District Court for the District of Delaware on February 9, 2026, alleging that compounded semaglutide injections and pills infringe on its patent covering the active pharmaceutical...more

Alston & Bird

DOJ’s Fraud Section Results for 2025 Signal Increased Enforcement Risk for Health Care and Life Sciences

Alston & Bird on

On January 22, 2026, the Fraud Section of the U.S. Department of Justice’s (DOJ) Criminal Division published its Year in Review for 2025. The report summarizes activity across the Fraud Section’s Health Care Fraud (HCF),...more

DLA Piper

Food and Beverage News and Trends - February 2026

DLA Piper on

This regular publication by DLA Piper lawyers focuses on helping clients navigate the ever-changing business, legal, and regulatory landscape. FDA releases 2026 deliverables for Human Foods Program. On January 23, the Food...more

McGuireWoods LLP

FDA’s PreCheck Pilot Program: What Manufacturers and Investors Need to Know

McGuireWoods LLP on

On Feb. 1, 2026, the FDA officially launched its Manufacturing PreCheck Pilot Program, which is intended to de-risk and accelerate the establishment of U.S. pharmaceutical manufacturing facilities by increasing regulatory...more

Husch Blackwell LLP

Understanding the Impact of the Vacated HIPAA Privacy Rule on Reproductive Healthcare

Husch Blackwell LLP on

Reproductive health privacy rule vacated. On June 18, 2025, the U.S. District Court for the Northern District of Texas vacated the HIPAA Privacy Rule to Support Reproductive Health Care Privacy Final Rule (Privacy Rule)....more

Epstein Becker & Green

FDA’s Office of Dietary Supplement Programs Signals Key Enforcement and Policy Priorities for the Year Ahead

Epstein Becker & Green on

During a recent industry webinar, Cara Welch, Ph.D., Director of the Office of Dietary Supplement Programs (“ODSP”) within the U.S. Food and Drug Administration (“FDA”), outlined the agency’s 2026 priorities for the dietary...more

Katten Muchin Rosenman LLP

Understanding FDA Records Access Under MoCRA

The U.S. Food and Drug Administration ("FDA") released a draft guidance document in January 2026 titled "FDA Records Access Authority for Cosmetic Products: Guidance for Industry" (the “Draft Guidance”). The Draft Guidance...more

Wilson Sonsini Goodrich & Rosati

Congress Reauthorizes the Rare Pediatric Disease Priority Review Voucher Program and Clarifies Orphan Drug Exclusivity

On February 3, 2026, the President signed the Consolidated Appropriations Act of 2026 (the CAA) into law and ended a partial government shutdown. The Act included two changes that directly affect pharmaceutical development:...more

61,009 Results
 / 
View per page
Page: of 2,441

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide